Pohla & Hallmagi, working with Osborne Clarke, has advised GeneCode on a EUR 2 million R&D grant from Enterprise Estonia for the acceleration of its GDNF Mimetics program.
Enterprise Estonia is a part of the Estonian Business and Innovation Agency, with an objective to develop the Estonian economy and businesses by evolving business models and boosting innovation, increasing export capacity, attracting high value-added foreign investment. and increasing tourism revenue.
GeneCode is a private pharmaceutical development company focused on the development of disease-modifying therapeutics to combat neurodegeneration.
According to GeneCode, Enterprise Estonia has confirmed its support for an applied research program to develop a small molecule glial cell line, Derived Neurotrophic Factor mimetics, for the treatment of Parkinson’s Disease and other indications. The applied research program has been created to help companies invest in early research and development to benefit from new or significantly improved technologies, products, and services and generate more profit.
Pohla & Hallmagi’s team included Partners Juri Ploom and Toivo Viilup.
